Other promising therapeutic approaches in pediatric and adult NHL in the R/R setting are antibody-drug conjugates (inotuzumab-ozogamicin, polatuzumab-vedotin, pinatuzumab-vedotin), CAR T-cell therapy (tisagenlecleucel), or strongly NHL subtype-dependent therapies targeting BTK (ibrutinib) [156]. Here, BTK is linked to non-Hodgkin lymphoma.